Cardiovascular risk and atherosclerosis prevention

被引:79
作者
Frohlich, Jiri [1 ]
Al-Sarraf, Ahmad [1 ]
机构
[1] St Pauls Hosp, Healthy Heart Program, Prevent Clin, Vancouver, BC V6Z 1Y6, Canada
关键词
Coronary artery disease; Framingham Heart Study; Risk scores; Lipoprotein (a); C-reactive protein; Myeloperoxidase; Lifestyle; Medications; C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; MYOCARDIAL-INFARCTION; PHYSICAL-ACTIVITY; RANDOMIZED-TRIAL; UNITED-KINGDOM; FOLLOW-UP; FRAMINGHAM; MEN; SCORE;
D O I
10.1016/j.carpath.2012.03.001
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Until recently, coronary artery disease (CAD) was the leading cause of death in the developed countries. Its remarkable decline can be attributed to our knowledge of the major risk factors identified by several studies resulting in better prevention and treatment. Of the major risk factors, the ratio of apolipoprotein (apo) B/apo A1 followed by smoking, diabetes, and hypertension are the most important. A number of risk scores for men and women are now available to estimate the likelihood of development of CAD. However, because of the risk of CAD differs in various populations, some of the algorithms are more appropriate for some countries but not suitable for others. These risk assessment algorithms differ in the parameters they use. All the risk scores have some limitations such as different study populations; the age of the study is also different, and number of points awarded for age categories also differs among the various algorithms. In an effort to further improve the risk prediction, a number of biomarkers have been studied. In addition to plasma lipids, a lot of interest has focused on apo measurements; particularly of apo B. Another valuable biomarker is lipoprotein (a) [Lp(a)]. Lp(a) is not only atherogenic as low-density lipoprotein (LDL) but also prothrombotic, and several studies indicate that Lp(a) is an independent risk factor for CAD. The lipid profile provides a framework for appropriate management. This includes therapeutic lifestyle changes and medications. Lifestyle interventions are the cornerstone of CAD prevention strategies and are the first step in risk factor management. Of particular importance are smoking cessation, achievement and maintenance of ideal body weight, regular exercise, reduction in the intake of saturated fat and sugars, and decreasing level of stress. Of medications, lipid-lowering, anti-hypertensive, and anti-coagulant can be effectively used. The current strategies for risk assessment and prevention have been very successful contributing to the more than 50% decrease in CAD mortality over the last 20 years. Thus, in Canada, cardiovascular disease is no longer the leading cause of death. Crown Copyright (c) 2013 Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:16 / 18
页数:3
相关论文
共 38 条
[1]
Niacin: From Mechanisms of Action to Therapeutic Uses [J].
Al-Mohaissen, M. A. ;
Pun, S. C. ;
Frohlich, J. J. .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2010, 10 (03) :204-217
[2]
[Anonymous], AM J PUBLIC HEALTH
[3]
Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study [J].
Assmann, G ;
Cullen, P ;
Schulte, H .
CIRCULATION, 2002, 105 (03) :310-315
[4]
Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene [J].
Benlian, P ;
DeGennes, JL ;
Foubert, L ;
Zhang, HF ;
Gagne, SE ;
Hayden, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (12) :848-854
[5]
Screening for Cardiovascular Risk in Asymptomatic Patients [J].
Berger, Jeffrey S. ;
Jordan, Courtney O. ;
Lloyd-Jones, Donald ;
Blumenthal, Roger S. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (12) :1169-1177
[6]
A METAANALYSIS OF PHYSICAL-ACTIVITY IN THE PREVENTION OF CORONARY HEART-DISEASE [J].
BERLIN, JA ;
COLDITZ, GA .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1990, 132 (04) :612-628
[7]
A PROSPECTIVE INVESTIGATION OF ELEVATED LIPOPROTEIN(A) DETECTED BY ELECTROPHORESIS AND CARDIOVASCULAR-DISEASE IN WOMEN - THE FRAMINGHAM HEART-STUDY [J].
BOSTOM, AG ;
GAGNON, DR ;
CUPPLES, LA ;
WILSON, PWF ;
JENNER, JL ;
ORDOVAS, JM ;
SCHAEFER, EJ ;
CASTELLI, WP .
CIRCULATION, 1994, 90 (04) :1688-1695
[8]
Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice: cross sectional population based study [J].
Cappuccio, FP ;
Oakeshott, P ;
Strazzullo, P ;
Kerry, SM .
BRITISH MEDICAL JOURNAL, 2002, 325 (7375) :1271-1274B
[9]
Estimation of ten-year risk of fatal cardiovascular disease in Europe:: the SCORE project [J].
Conroy, RM ;
Pyörälä, K ;
Fitzgerald, AP ;
Sans, S ;
Menotti, A ;
De Backer, G ;
De Bacquer, D ;
Ducimetière, P ;
Jousilahti, P ;
Keil, U ;
Njolstad, I ;
Oganov, RG ;
Thomsen, T ;
Tunstall-Pedoe, H ;
Tverdal, A ;
Wedel, H ;
Whincup, P ;
Wilhelmsen, L ;
Graham, IM .
EUROPEAN HEART JOURNAL, 2003, 24 (11) :987-1003
[10]
The prevention of type 2 diabetes [J].
Crandall, Jill P. ;
Knowler, William C. ;
Kahn, Steven E. ;
Marrero, David ;
Florez, Jose C. ;
Bray, George A. ;
Haffner, Steven M. ;
Hoskin, Mary ;
Nathan, David M. .
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2008, 4 (07) :382-393